Interim Report April - December 2024
Regulatory
Sales and operating profit growth, significant product acquisition signed
Welcome to EQL Pharma's Investor Pages!
We strive to have an open and proactive dialogue with our shareholders.
Read MoreInterim Report Q3 2024/2025
Listen to CEO Axel Schörling present EQL Pharma's latest report.
Interim Report Q3 2024/2025Press Releases
EQL Pharma AB completes the asset purchase of a product portfolio from Medilink A/S
Regulatory
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OR TO ANY PERSON LOCATED OR RESIDENT IN ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL OR WOULD REQUI...
EQL Pharma invites to Capital Markets Day, March 7, 2025
EQL Pharma AB (publ), a leading Niche Pharmaceuticals Company, is pleased to invite investors and other interested parties to a Capital Markets Day (CMD) on Friday, March 7, 2025.
EQL Pharma in Short
EQL Pharma is an entrepreneurial pharmaceutical company focusing on simplicity and efficiency at all levels of the value chain in order to be able to deliver cost-efficient medicines of highest quality to pharmacies and hospitals.
Read more about usFinancial Calendar
08May2025
Year End Report Q4